谷胱甘肽对2型糖尿病周围神经病变患者血清氧化应激指标及感觉神经传导速度的影响

目的 观察2型糖尿病周围神经病变患者血清氧化应激相关指标的变化,探讨抗氧化剂--谷胱甘肽(GSH)对2型糖尿病周围神经病变患者的神经保护作用.方法 检测54例2型糖尿病周围神经病变患者(研究组)与30例健康体检者(对照组)血清中丙二醛(MDA)含量与超氧化物歧化酶(SOD)活性;将54例2型糖尿病周围神经病变患者按随机数字表法分为GSH组和CON组,每组27例.GSH组予GSH 1.8 g/d,CON组予B族维生素治疗,均治疗14 d.分别检测两组治疗前后MDA含量、SOD活性、双侧胫后感觉神经传导速度(SCV).结果 研究组MDA含量(7.23 ±2.31) μmol/L和SOD活性(59.72±13.58) kU/L,对照组MDA含量(4.87 ±1.17)μmol/L和SOD活性(76.19 ± 7.55)kU/L,研究组MDA含量高于对照组,SOD活性低于对照组,两组比较差异有统计学意义(P＜0.01);GSH组和CON组治疗后MDA含量下降,SOD活性升高,治疗前后比较差异有统计学意义(P＜0.05),但两组治疗后比较差异无统计学意义(P＞0.05).CON组治疗后SCV虽有上升但与治疗前比较差异无统计学意义(P＞0.05),而GSH组治疗后SCV显著增加(P＜0.05),两组治疗后比较差异有统计学意义(P＜0.05).结论 2型糖尿病周围神经病变患者体内存在氧化应激反应,GSH抗氧化治疗可以改善受损神经,较传统的营养神经治疗有较好的神经保护作用.

Abstract：

Objective To observe the change of oxidalive stress indexes in the patients with diabetic perineuropathy (DPN), and investigate the protection role of glutathione (GSH) on neuroprotective effect. Methods The levels of superoxide dismutase (SOD) and malondialdehyde (MDA) and sensory nerve conduction velocity (SCV) were detected in 54 cases with DPN (DPN group) and 30 cases of health examination (control group). Fifty-four cases with DPN were divided into GSH group (given basic treatment and GSH 1.8 g/d) and CON group(given basic treatment and B vitamin) with 27 cases each by random-digits table. After treatment of 2 weeks, the levels of SOD, MDA and SCV were compared. Results The levels of MDA in DPN group were significantly higher than those in control group, while the activity of SOD was significantly lower than that in control group [(7.23 ±2.31) μmol/L vs. (4.87 ± 1.17) μmol/L, (59.72 ± 13.58) kU/L vs. (76.19 ± 7.55 ) kU/L](P＜ 0.01). After treatment, the level of MDA was decreased and the activity of SOD was increased in GSH group and CON group (P ＜0.05),but there was no significant difference between the two groups(P＞ 0.05). After treatment, the level of SCV was significantly increased in GSH group,while there was no significant difference in CON group (P ＞0.05). Conclusions Oxidative stress exists in DPN patients. The antioxidant treatment with GSH can improve impaired nerve and has a better effect of nerve protection than classical nerve nutrition therapy.     

伴H3 K27M突变的儿童弥漫性中线胶质瘤的临床特点、治疗及预后

目的探讨伴H3 K27M突变的儿童弥漫性中线胶质瘤(DMG)的临床特点、治疗及预后。方法回顾性分析2017年7月至2020年3月首都医科大学附属北京儿童医院神经外科收治的10例DM G伴H3 K27M突变患儿的临床资料。10例患儿中,病变位于丘脑4例,脑干4例,脊髓2例,其中行开颅肿瘤切除术7例,脊髓肿瘤切除术2例,颅内病变活组织检查术1例4例术后行放疗联合化疗,1例行单纯放疗,5例未行放疗或化疗以肿瘤切除率>90%为近全切除,50%~90%为部分切除。术后随访至2020年7月或患儿死亡,随访患儿肿瘤有无进展、生存时间以及死亡原因。结果10例患儿的中位发病年龄为8.9(4.9~9.9)岁,颅内占位临床表现为头痛、恶心、呕吐、肢体无力、癫痫发作、意识障碍及脑神经麻痹;脊髓占位临床表现为进行性肢体无力。肿瘤近全切除4例,部分切除5例,活组织检查术1例。患儿术后症状改善6例,无改变4例;无一例出现中枢神经系统感染;1例在术后放疗期间出现脑积水10例患儿的肿瘤病理学结果均为DMG伴H3 K27M突变(世界卫生组织肿瘤分级Ⅳ级);免疫组织化学检测结果显示,少突胶质细胞转录因子2阳性比例为9/9,胶质纤维酸性蛋白阳性比例为10/10,突变型异柠檬酸脱氢酶1阳性比例为0/9,Ki-67≥40%的比例为8/10。10例患儿术后均得到有效随访;随访时间为1~23个月至末次随访,2例患儿存活,8例患儿因肿瘤进展死亡,生存时间为1~23个月结论初步观察发现,伴H3 K27M突变的儿童DMG临床表现多样,可选择手术、术后放疗和(或)化疗治疗,患儿的生存预后差。     

2型糖尿病合并急性冠脉综合征患者循环内皮祖细胞变化的研究

目的 观察2型糖尿病合并急性冠脉综合征(ACS)患者循环内皮祖细胞(EPCs)数量及功能的变化,探究EPCs参与糖尿病大血管病变发生的机制.方法 2型糖尿病患者42例、2型糖尿病合并ACS患者45例和健康志愿者40例.用密度梯度离心法分离单个核细胞,流式细胞仪检测循环EPCs数量；体外培养观察EPCs迁移能力.结果 与正常对照组比较,2型糖尿病患者和2型糖尿病合并ACS患者EPCs数量明显减少(P＜0.01)；2型糖尿病合并ACS患者较单纯2型糖尿病患者的EPCs数量减少(P＜0.01).2型糖尿病合并ACS及2型糖尿病患者循环EPCs迁移能力较正常对照组明显下降(P＜0.01),2型糖尿病合并ACS患者较单纯2型糖尿病患者EPCs迁移能力也有下降(P＜0.05).结论 2型糖尿病合并ACS患者循环EPCs数量减少、功能受损,可能参与2型糖尿病大血管并发症的发生和发展.